简介:
- 作者: Wei Feng, Julijus Bogomolovas, Abraham Grant Shain, Li Wang, Chao Chen, Mao Ye, Yusu Gu, Xiaohai Zhou, Ju Chen
- 杂志: Circulation
- Doi: https://www.doi.org/10.1161/CIRCULATIONAHA.125.074632
- 出版日期: 2025/11/19
摘要
ALPK3 (alpha protein kinase 3) is characterized by its unique alpha kinase domain and is localized to the M band in cardiomyocytes to maintain sarcomere integrity, functioning as a pseudokinase1,2. Individuals harboring homozygous or compound heterozygous loss-of-function ALPK3 mutations present severe cardiomyopathy at birth, or in early childhood3. Heterozygous ALPK3 variants are associated with adult hypertrophic cardiomyopathy4. Consequently, restoring ALPK3 expression emerges as a promising approach for treating cardiomyopathy resulting from ALPK3 deficiency.
In exploring therapeutic strategies, we attempted to use the adeno-associated virus (AAV) vector to deliver full-length Alpk3 cDNA to cardiomyocytes in global Alpk3 knockout (Alpk3−/−) mice. These mice recapitulate the clinical manifestations of cardiomyopathies in human patients with homozygous loss-of-function ALPK3 mutations and provide a reliable model for studying ALPK3-associated cardiomyopathies1,4. All animal procedures adhered to institutional guidelines and received approval from the Institutional Animal Care and Use Committee (IACUC). However, the full-length Alpk3 coding region spans 5,040 bp, which exceeds the AAV packaging limit of 4.7 kb. ALPK3 is encoded by 14 exons, with exon 6 alone contributing to 40% of the coding sequence. Given that this region is predicted to be intrinsically disordered by in silico disorder prediction tools, we sought to generate a truncated version of ALPK3 through an in-frame deletion of a large portion of exon 6, with the goal of preserving protein functionality. Using CRISPR-Cas9, we successfully removed a 1,119 bp segment from exon 6 to create a miniALPK3 variant (Figure A). Sequencing confirmed the deletion of amino acids in exon 6 (Figure B). Mice homozygous for miniALPK3 exhibited normal cardiac function for up to 15 months of age (Figure C), demonstrating that miniALPK3 retains the functional properties of the full-length protein in the heart.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。